drugset / Trial / NCT03216525

Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol

NCT03216525

RandomizedParallel-groupDouble-blindTreatment

Summary

To determine if Alvimopan during open or robotic radical cystectomy with urinary diversion results in quicker return of bowel function (GI-2 recovery = time to upper \[first toleration of solid food\] and lower \[first bowel movement\] gastrointestinal recovery) compared to placebo.

Timeline

Start
2018-10-01
Primary completion
2023-12-01
Completion
2024-06-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alvimopan Small molecule 12 mg Oral